Stock KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NewAmsterdam Pharma Company N.V. Börse Stuttgart

Equities

KH6

NL00150012L7

Biotechnology & Medical Research

Market Closed - Börse Stuttgart
Other stock markets
 02:14:32 2024-07-12 pm EDT 		5-day change 1st Jan Change
18 EUR -5.76% Intraday chart for NewAmsterdam Pharma Company N.V. +4.95% +92.93%
Jul. 08 NewAmsterdam Pharma Completes Enrollment for Phase 3 Trial of Potential Cardiovascular Disease Treatment MT
Jul. 08 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 - 830.7 833.1 1,732 - -
Enterprise Value (EV) 1 - 392.2 833.1 1,732 1,732 1,732
P/E ratio -3.39 x -10.6 x -5.1 x -7.82 x -12.2 x -12.5 x
Yield - - - - - -
Capitalization / Revenue - 8.52 x 64.1 x 201 x 274 x 110 x
EV / Revenue - 8.52 x 64.1 x 201 x 274 x 110 x
EV / EBITDA - - - - - -
EV / FCF - 104 x -6.39 x -9.81 x -13.8 x -12.1 x
FCF Yield - 0.96% -15.6% -10.2% -7.26% -8.27%
Price to Book - 1.71 x - - - -
Nbr of stocks (in thousands) - 81,560 82,324 89,986 - -
Reference price 2 8.575 10.19 10.12 18.26 18.26 18.26
Announcement Date 8/4/22 3/31/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 97.5 13.01 8.638 6.311 15.7
EBITDA - - - - - -
EBIT 1 - -6.96 -168.9 -187.1 -158.2 -160.4
Operating Margin - -7.14% -1,298.56% -2,165.65% -2,506.62% -1,022.14%
Earnings before Tax (EBT) 1 - -78.05 -163.3 -206.9 -135.9 -141.2
Net income 1 -28.6 -78.05 -163.3 -209.6 -139 -140
Net margin - -80.05% -1,255.76% -2,426.8% -2,201.76% -892.03%
EPS 2 -2.530 -0.9600 -1.984 -2.334 -1.500 -1.455
Free Cash Flow 1 - 7.959 -130.4 -176.6 -125.7 -143.3
FCF margin - 8.16% -1,002.43% -2,044.09% -1,991.99% -912.83%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/4/22 3/31/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S2 2023 S1 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4 9.562 1.304 1.11 1.843 4.557 - -
EBITDA - - - - - - - -
EBIT 1 - - -51.63 -50.47 -45.72 -39.52 -41.86 -37.26
Operating Margin - - -3,960.17% -4,545.76% -2,480.93% -867.18% - -
Earnings before Tax (EBT) 1 - - -93.77 -47.49 -41.92 -37.15 -38.47 -33.85
Net income 1 - -75.1 -93.77 -48.27 -42.27 -37.69 -38.47 -33.85
Net margin - -785.42% -7,192.76% -4,347.76% -2,294.09% -827.04% - -
EPS 2 - -0.9200 -0.9863 -0.5389 -0.4673 -0.4146 -0.3942 -0.3480
Dividend per Share - - - - - - - -
Announcement Date 3/31/23 8/7/23 5/8/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - 439 - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - 7.96 -130 -177 -126 -143
ROE (net income / shareholders' equity) - -29.2% - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 5.940 - - - -
Cash Flow per Share - 0.1000 - - - -
Capex 1 - 0.01 0.02 0.92 1.85 2.77
Capex / Sales - 0.01% 0.17% 10.7% 29.3% 17.67%
Announcement Date 8/4/22 3/31/23 2/28/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for NewAmsterdam Pharma Company N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.26 EUR
Average target price
35.08 EUR
Spread / Average Target
+92.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 117B
ARGENX SE Stock argenx SE
+25.56% 27.77B
BIONTECH SE Stock BioNTech SE
-19.51% 20.44B
GENMAB A/S Stock Genmab A/S
-14.36% 16.62B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 15.92B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.74B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. KH6 Stock
  5. Financials NewAmsterdam Pharma Company N.V.